Davita Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.47 (market cap $27.76B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 2.5× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| DVA | LQD | |
|---|---|---|
Market Cap | $11.29B | $27.76B |
Volume | 582,204 | 30,088,564 |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $112.91 |
52-Week Low | $103.87 | $101.83 |
Typical Hold Time | 113 Days | 125 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
LQD trades at $102.12, down 0.02% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The ETF faces headwinds from rising bond yields and a significant 53.1% increase in short interest reported as of September 15, 2026. Recent dividends include $0.44 and $0.46 payouts scheduled through October 2026, providing income support.
Outlook remains cautious due to persistent bond market volatility and higher interest rates, which pressure corporate bond ETFs. Investment opportunities lie in the 4.8% yield and high-quality portfolio, but risks include further yield spikes and economic slowdowns affecting credit quality.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →